Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R. D´Aquila, V.A. Johnson, S. Welles, A.J. Japour, D.R. Kuritzkes, V. De Gruttola, et al.
Zidovudine resístanse and human immunodeficiency virus type 1 disease progresión during antiretroviral therapy.
Ann Intern Med, 122 (1995), pp. 401-408
[2.]
A.J. Japour, S. Welles, R.T. D´Aquila, V.A. Johnson, D.D. Richman, R.W. Coombs, et al.
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after longterm zidovudine treatment.
J Infect Dis, 171 (1995), pp. 1.172-1.179
[3.]
C. Pérez de Oteyza, M.A. Menéndez, C. Pérez Aznar, M. Carmona de Cozar, R. Muro.
Respuesta de carga viral y linfocitos CD4+ a un año de tratamiento antirretroviral triple en pacientes VIH pretratados.
Rev Clin Española, 200 (Supl 1 (2000), pp. 71
[4.]
F.J. Jr Palella, K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, et al.
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.
N Engl J Med, 338 (1988), pp. 853-860
[5.]
El Grupo de Estudio de Sida de la SEIMC, la Sociedad Española de Farmacia Hospitalaria y la Secretaría del Plan Nacional sobre el Sida. Recomendaciones para mejorar la adherencia al tratamiento antirretrovírico. Ministerio de Sanidad y Consumo, 1999
[6.]
A.S. Perelson, A.U. Neumann, M. Markowitz, J.M. Leonard, D.D. Ho.
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and virica generation time.
Science, 271 (1996), pp. 1.582-1.586
[7.]
J.M. Coffin.
HIV population dynamics in vivo: implication for genetic variation, pathogenesis, and therapy.
Science, 267 (1995), pp. 483-489
[8.]
J. Martínez Picado, L.V. Savara, L. Sutton, R.T. D´Aquila.
Replicative fitness of proteasa inhibitor-resistant mutants of human immunodeficiency virus type 1.
J Virol, 73 (1999), pp. 3.744-3.752
[9.]
M. Leal, J.M. Santamaría.
Resistencia a los inhibidores de la transcriptasa inversa análogos de nucleósidos.
Enferm Infec Microbiol Clin, 19 (Monográfico (2001), pp. 26-29
[10.]
K. Van Vaerenbergh, K. Van Laethem, J. Albert, C.A. Boucher, B. Clotet, M. Floridia, et al.
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.
Antimicrob Agents Chemother, 44 (2000), pp. 2.109-2.117
[11.]
V. Miller, A. Phillips, C. Rottmann, S. Staszewski, R. Pauwels, K. Hertogs, et al.
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy.
J Infect Dis, 177 (1998), pp. 1.521-1.532
[12.]
S.G. Deeks, N.S. Hellman, R.M. Grant, N.T. Parkin, C.J. Petropoulos, M. Becker, et al.
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen.
J Infect Dis, 179 (1999), pp. 1.375-1.381
[13.]
Lorenzi P, Opravil M, Hirschel B, Chave JP, Sax H, Furrer HJ|, |xet al. Resistance mutations as predictor of response to salvage therapy. 6th Conference on Retroviruses And Opportunistic Infections. Chicago IL: 1999 (Abstract 140)
[14.]
A.R. Zolopa, R.W. Shafer, A. Warford, J.G. Montoya, D. Katzenstein, T. Merigan.
HIV-1 genotypic resistence patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.
Ann Intern Med, 131 (1999), pp. 813-822
[15.]
P. Clevenbergh, J. Durant, P. Halfon, P. del Guiudice, P. Simonet, N. Montagne, et al.
Persisting long-term benefit of antirretroviral genotypic guided treatment for HIV-infected patients failing HAART.
Antiviral Ther, 4 (1999), pp. 42
[16.]
J.D. Baxter, D.L. Mayers, D.N. Wentworth, J.D. Neaton, T.C. Merigan.
Final results of CPCRA 046: a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy.
Antiviral Ther, 4 (1999), pp. 43
[17.]
C. Cohen, H. Kessler, S. Hunt, M. Sension, C. Farthing, M. Conant, et al.
Phenotypic resistance testing significantly improves response to therapy: final analysis of a randomized trial (VIRA3001). 4th International Workshop o Drug Resistance and Treatment Strategies. Sitges (Spain), 12-16 June 2000 (Abstract 84.
Antiviral Ther, 5 (Supl 3 (2000), pp. 67
[18.]
D.V. Havlir, N.S. Hellman, C.J. Petropoulos, J.M. Whitcomb, A.C. Collier, M.S. Hirsch, et al.
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
JAMA, 283 (2000), pp. 229-234
[19.]
D. Descamps, P. Flandre, V. Calvez, G. Peytavin, V. Meiffredy, G. Collin, et al.
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial induction-maintenance therapy.
JAMA, 283 (2000), pp. 205-211
[20.]
M. Markowitz.
Resístance, fitness, adherence and potency. Mapping the paths to virologic failure.
JAMA, 283 (2000), pp. 250-251
[21.]
B. Clotet, J. Martínez-Picado, L. Ruíz, C. Tural.
Resistencia a los fármacos antirretrovirales.
[22.]
S.H Oari, R. Respess, H. Weinstock, E. Beltrami, K. Hertogs, B.A. Larder, et al.
A comparative analysis of Virco Antivirogram and Virologic PhenoSense Phenotipyc assays for drug susceptibility of HIV-1. 4th International Workshop in Drug Resistance and Tratment Strategies. Sitges (Spain), 12-16 June 2000 (Absrtact 62.
Antiviral Ther, 5 (Supl 3 (2000), pp. 49
[23.]
L. Ruiz, J. Martínez-Picado, B. Clotet.
Resistencia del VIH a los antirretrovirales.
Guía Práctica del Sida: Clínica, diagnóstico y tratamiento. (6ª ed), pp. 413-426
[24.]
M.S. Hirsch, F. Brun-Vézinet, R.T. D´Aquila, S.H. Hammer, V.A. Johnson, D.R. Kuritzkes, et al.
Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an international AIDS Society-USA Panel.
JAMA, 283 (2000), pp. 2.417-2.426
[25.]
J.M. Miró, A. Antela, J. Arrizabalaga, B. Clotet, J.M. Gatell, L. Guerra, et al.
Recomendaciones de GESIDA/Plan Nacinal sobre el Sida respecto al tratamiento antirretrovírico en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2000 (II.
Enferm Infec Microbiol Clin, 18 (2000), pp. 396-412
[26.]
A. Antela, J.A. Iribarren, B. Clotet, L. Guerra.
Documentos de consenso y guías clínicas sobre resistencia a antirretrovirales.
Enferm Infec Microbiol Clin, 19 (Monográfico (2001), pp. 47-52
[27.]
T. Puig, M. Pérez-Olmeda, A. Rubio, L. Ruiz, C. Briones, J.M. Franco, et al.
Prevalence of genotypic resistanse to nucleoside analogues and protease inhibitors in Spain.
AIDS, 14 (2000), pp. 727-732
[28.]
E.M. Connor, R.S. Sperling, R. Gelber, P. Kiselev, G. Scott, M.J. O´Sullivan, et al.
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment.
N Engl J Med, 331 (1994), pp. 1.173-1.180
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
